Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer

Imran, Mohammad; Saleem, Sadaf; Chaudhuri, Aiswarya; Ali, Javed; Baboota, Sanjula

doi:10.1016/j.jddst.2020.101959

Cited by 72 publications

(64 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been at least two recent reviews regarding NP research specifically intended for use in prostate cancer as detailed in Table 1 ( Barani et al, 2020 ; Imran et al, 2020 ; Lorenc et al, 2020 ). The main roles for nanosystems in the treatment of PC may rest with the minimization of off-target effects and increasing the therapeutic index of cytotoxic agents, as well in increasing radiosensitivity by delivery of radiosensitising agents.…”

Section: Applications Of Nanoparticles In Male Reproductive Health Medicine and Researchmentioning

confidence: 99%

Biocompatible Nanomaterials as an Emerging Technology in Reproductive Health; a Focus on the Male

et al. 2021

View full text Add to dashboard Cite

A growing body of research has confirmed that nanoparticle (NP) systems can enhance delivery of therapeutic and imaging agents as well as prevent potentially damaging systemic exposure to these agents by modifying the kinetics of their release. With a wide choice of NP materials possessing different properties and surface modification options with unique targeting agents, bespoke nanosystems have been developed for applications varying from cancer therapeutics and genetic modification to cell imaging. Although there remain many challenges for the clinical application of nanoparticles, including toxicity within the reproductive system, some of these may be overcome with the recent development of biodegradable nanoparticles that offer increased biocompatibility. In recognition of this potential, this review seeks to present recent NP research with a focus on the exciting possibilities posed by the application of biocompatible nanomaterials within the fields of male reproductive medicine, health, and research.

show abstract

Section: Applications Of Nanoparticles In Male Reproductive Health Medicine and Researchmentioning

confidence: 99%

Biocompatible Nanomaterials as an Emerging Technology in Reproductive Health; a Focus on the Male

et al. 2021

View full text Add to dashboard Cite

show abstract

“…DTX, although it is more water-soluble and is typically formulated in a polyoxyethylene (20) sorbitan monooleate (polysorbate 80): ethanol:saline carrier and administered as an aqueous intravenous solution, still has some side effects, owing to its non-specific targeting behavior [17,18]. As a chemotherapeutic drug, DTX is mainly used for the treatment of breast, ovarian, prostate, and non-small cell lung cancer, but it causes neutropenia, hy-persensitivity reactions, peripheral neuropathy, musculoskeletal toxicity, and nasolacrimal duct stenosis [18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

“…As a chemotherapeutic drug, DTX is mainly used for the treatment of breast, ovarian, prostate, and non-small cell lung cancer, but it causes neutropenia, hy-persensitivity reactions, peripheral neuropathy, musculoskeletal toxicity, and nasolacrimal duct stenosis [18][19][20][21]. To improve its therapeutic outcomes and evade associated side effects, delivery strategies for DTX have been widely investigated [17,22]. As for treatment of prostate cancer, the prostate specific membrane antigen (PSMA), a transmembrane protein expressed by virtually all prostate cancers, has been suggested to be an important target for DTX treatment [23].…”

Section: Introductionmentioning

confidence: 99%

“…In other studies, conjugation of DTX to specific ligands shows increased solubility and targeting [26], controlled-release, and low systemic toxicity [25,27]. Nanoformulation techniques using various nanocarriers have also provided sustained release at adequate concentrations and have thus greatly improved DTX targeting to tumors [17]. Additionally, when co-delivered in combination with other anti-cancer drugs using nanoparticles PE-Gylation, DTX exhibited enhanced overall efficacy with no apparent toxicity that could be due to better delivery and targeting [17,28].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment

Rayan

Shadafny²,

Falah

et al. 2022

Molecules

View full text Add to dashboard Cite

A novel conjugate of docetaxel and biotin (designated as IDD-1010) was designed and chemically synthesized via an ester linkage at position 2’ carbon in docetaxel. The synthesized pure IDD-1010 exhibits a potent anti-cancer activity in in vitro and in vivo studies. At 10 nM, IDD-1010 has induced increased apoptosis and mitotic arrest of PC3-Luc prostate cancer cells, causing aneuploidy and cell death at higher concentrations. Toxicology studies indicate that the maximal tolerated dose (MTD) of IDD-1010 is 150 mg/kg in mice; equivalent to about 12.2 mg/kg of body weight, or to about an 850 mg dose for a patient weighing 70 kg. The MTD-treated mice exhibited weight gain similar to that of the control group, with no gross pathological signs at 14 days post-dosing. At a lower dose, IDD-1010 treatment did not lead to any significant weight loss in mice, although decreased the tumor volume stemming from injecting cancer cells into the dorsal loop of mouse prostate, and it was found to be more potent than Paclitaxel (reference drug). Similarly, IDD-1010 treatment significantly reduced tumor weight and thereby increased the percentage of mice survival as compared to reference drug-treated and control groups. To summarize, the described experiments using IDD-1010, as compared to the reference drug, strongly suggest a potential treatment utility with a wider therapeutic window for prostate cancer. Henceforth, clinical research on such a novel drug candidate would be greatly worthwhile.

show abstract

“…The taxanes in particular represent an important class of anticancer drugs that are frequently prescribed to treat a wide variety of solid tumors [ 2 ]. Docetaxel (DTX) is a potent taxane that binds to microtubules with high affinity to promote cell cycle arrest and subsequent apoptosis and is approved to treat cancers including breast cancer, non-small cell lung cancer, and castration-resistant prostate cancer [ 3 , 4 ]. Like many other chemotherapeutics, it is poorly water-soluble, requiring a mixture of Tween 80 and ethanol to effectively solubilize the drug for intravenous (IV) injection [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Oligo(Lactic Acid)8-Docetaxel Prodrug-Loaded PEG-b-PLA Micelles for Prostate Cancer

Repp

Unterberger

et al. 2021

Nanomaterials

View full text Add to dashboard Cite

Docetaxel (DTX) is among the most frequently prescribed chemotherapy drugs and has recently been shown to extend survival in advanced prostate cancer patients. However, the poor water solubility of DTX prevents full exploitation of this potent anticancer drug. The current marketed formulation, Taxotere®, contains a toxic co-solvent that induces adverse reactions following intravenous injection. Nano-sized polymeric micelles have been proposed to create safer, water-soluble carriers for DTX, but many have failed to reach the clinic due to poor carrier stability in vivo. In this study, we aimed to improve micelle stability by synthesizing an ester prodrug of DTX, oligo(lactic acid)8-docetaxel (o(LA)8-DTX), for augmented compatibility with the core of poly(ethylene glycol)-b-poly(lactic acid) (PEG-b-PLA) micelles. Due to the enhancement of drug-carrier compatibility, we were able to load 50% (w/w) prodrug within the micelle, solubilize 20 mg/mL o(LA)8-DTX (~12 mg/mL DTX-equivalent) in aqueous media, and delay payload release. While the micelle core prohibited premature degradation, o(LA)8-DTX was rapidly converted to parent drug DTX through intramolecular backbiting (t1/2 = 6.3 h) or esterase-mediated degradation (t1/2 = 2.5 h) following release. Most importantly, o(LA)8-DTX micelles proved to be as efficacious but less toxic than Taxotere® in a preclinical mouse model of prostate cancer.

show abstract

Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer

Cited by 72 publications

References 116 publications

Biocompatible Nanomaterials as an Emerging Technology in Reproductive Health; a Focus on the Male

Biocompatible Nanomaterials as an Emerging Technology in Reproductive Health; a Focus on the Male

A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment

Oligo(Lactic Acid)8-Docetaxel Prodrug-Loaded PEG-b-PLA Micelles for Prostate Cancer

Contact Info

Product

Resources

About